Alexion Pharmaceuticals (NASDAQ:ALXN) was downgraded by equities research analysts at TheStreet from a "b-" rating to a "c" rating in a research note issued on Thursday, TheStreetRatingsTable reports.
A number of other equities analysts have also recently commented on ALXN. JPMorgan Chase & Co. lowered their target price on Alexion Pharmaceuticals from $168.00 to $163.00 and set an "overweight" rating for the company in a report on Friday, April 17th. Cantor Fitzgerald assumed coverage on Alexion Pharmaceuticals in a research report on Monday, April 27th. They issued a "neutral" rating and a $121.00 price target on the stock. William Blair lowered Alexion Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Thursday. Zacks Investment Research lowered Alexion Pharmaceuticals from a "buy" rating to a "hold" rating and set a $107.00 price target on the stock. in a research report on Monday, May 18th. Finally, UBS Group reaffirmed a "reduce" rating on shares of Alexion Pharmaceuticals in a research report on Monday, April 20th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of "Buy" and an average price target of $143.17.
Shares of Alexion Pharmaceuticals stock opened at $102.49 on Thursday. The business has a 50-day moving average of $110.49 and a 200 day moving average of $102.94. Alexion Pharmaceuticals has a 12 month low of $72.67 and a 12 month high of $125.52. The stock has a market capitalization of $22.63 billion, a price-to-earnings ratio of 27.40, a price-to-earnings-growth ratio of 0.83 and a beta of 1.46. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.79 and a quick ratio of 3.82.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $3.11 EPS for the quarter, beating analysts' consensus estimates of $2.32 by $0.79. Alexion Pharmaceuticals had a return on equity of 22.57% and a net margin of 15.28%. The company had revenue of $1.44 billion during the quarter, compared to analysts' expectations of $1.27 billion. Equities research analysts anticipate that Alexion Pharmaceuticals will post 9.95 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in the business. Guggenheim Capital LLC boosted its stake in shares of Alexion Pharmaceuticals by 1.1% in the fourth quarter. Guggenheim Capital LLC now owns 313,498 shares of the biopharmaceutical company's stock valued at $33,905,000 after buying an additional 3,378 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Alexion Pharmaceuticals by 114.9% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,756 shares of the biopharmaceutical company's stock valued at $706,000 after buying an additional 3,612 shares in the last quarter. Sunbelt Securities Inc. purchased a new stake in shares of Alexion Pharmaceuticals in the fourth quarter valued at approximately $8,111,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of Alexion Pharmaceuticals by 36.4% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 21,114 shares of the biopharmaceutical company's stock valued at $2,271,000 after buying an additional 5,629 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in shares of Alexion Pharmaceuticals by 253.5% in the fourth quarter. Quadrant Capital Group LLC now owns 813 shares of the biopharmaceutical company's stock valued at $82,000 after buying an additional 583 shares in the last quarter. Institutional investors own 89.07% of the company's stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Story: Google Finance Portfolio
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Technology Stocks that Analysts Love
There are more than 1,100 technology companies traded on public markets in the United States. Given the sheer number of hardware makers, social networks, software companies, service providers and other tech stocks, it can be hard to identify which tech companies are going to outperform the market.
Fortunately, Wall Street's brightest minds have already done this for us. Every year, analyst issue approximately 15,000 distinct recommendations for technology companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same tech stock.
This slide show lists the 15 technology companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "15 Technology Stocks that Analysts Love".